Drug Trial Radar · NCT00621504
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
Last checked: Nov 19, 2026Latest source record: Mar 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
606
Actual
Start
Jan 2008
Primary completion
Dec 2008
Study completion Jun 2009
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 22, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia
Conditions
- Bacterial Pneumonia
Interventions
Ceftaroline fosamil for InjectionDrug
2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
IV CeftriaxoneDrug
1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
PlaceboDrug
Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
ClarithromycinDrug
In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Cure Rate at Test-of-Cure (TOC) in the Modified Intent-to-Treat Efficacy (MITTE) PopulationsTime frame: 8 to 15 days after last dose of study drug
- Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test-of-Cure (TOC) in the Clinically Evaluable (CE) PopulationTime frame: 8-15 days after last dose of study drug
Locations
168 sites in 23 countries. Site status is shown where the registry gives one.
Investigational site
Los Angeles, California
Investigational Site
Pasadena, California
Investigational Site
Sacramento, California
Investigational Site
San Diego, California
Investigational Site
Orlando, Florida
Investigational Site
Fort Gordon, Georgia
Investigational Site
Peoria, Illinois
Investigational Site
Baltimore, Maryland
Investigational site
Minneapolis, Minnesota
Investigational Site
Butte, Montana
Investigational Site
Akron, Ohio
Investigational Site
Houston, Texas
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Buenos Aires, Argentina
Investigational Site
Vicente López, Argentina
Investigational Site
Buenos Aires, C.a.b.a., Argentina
Investigational Site
San Miguel de Tucumán, Tucumán Province, Argentina
Investigational Site
Vienna, Austria
Investigational Site
Vienna, Austria
Investigational Site 2
Belo Horizonte, Brazil
Investigational Site 1
Belo Horizonte MG, Brazil
Investigational Site
Campinas, Brazil
Investigational Site
Curitiba-PR, Brazil
Investigational Site
Juiz de Fora, Brazil
Investigational site
Porto Alegre, Brazil
Investigational Site
São Paulo, Brazil
Investigational Site
São Paulo, Brazil
Investigational Site
Goiânia, G.o., Brazil
Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Investigational Site
São José do Rio Preto, São Paulo, Brazil
Investigational Site
Burgas, Bulgaria
Investigational Site
Sofia, Bulgaria
Investigational Site
Varna, Bulgaria
Investigational Site
Tallinn, Estonia
Showing 40 of 168 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.